PFE - Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology | Benzinga
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to COVID-19 vaccines.
Acuitas is developing lipid nanoparticle (LNP) technology used in mRNA vaccines and other therapeutics under development.
Acuitas's R&D resulted in its lipids and LNP technology being used to deliver the mRNA payload in the Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine, Comirnaty Reuters writes.
Acuitas told the court that CureVac omitted its scientists from patent applications for lipid nanoparticle technology used in messenger RNA-based ...